ABSTRACT
On November 23, 2015 in Protvino of the Moscow Region there was begun proton therapy using Russia's first medical therapeutic complex "Prometheus" produced by JSC "PRO- TOM" and certified to treat patients with head and neck tumors. The complex allows irradiating patients with active scanning beam. Energy of beam is 30-250MeV and maximum field size is 10 cm vertically and 40 cm horizontally. The manufacturer declared parameters were confirmed during preclinical stud- ies. By April 8, 2016 the successful proton therapy received 20 patients with complex "targets" mostly located, from the point of view of radiation tolerance, near the critical structures.
Subject(s)
Head and Neck Neoplasms/radiotherapy , Proton Therapy , Humans , Proton Therapy/instrumentation , Proton Therapy/methods , Proton Therapy/trends , RussiaABSTRACT
This study presents the short-term outcomes of conformal external beam radiation therapy given in conjunction with hormone therapy to 110 patients with prostate cancer. We performed a comparative analysis of the rate and degree of radiation reactions and complications following delivery of a total dose of 70 Gy and 72-76 Gy to the tumor. In prostate cancer, a continuous course of dose-escalated conformal radiation therapy resulted in satisfactory tolerance and acceptable levels of late complications.
Subject(s)
Adenocarcinoma/drug therapy , Adenocarcinoma/radiotherapy , Antineoplastic Agents, Hormonal/therapeutic use , Cystitis/etiology , Proctitis/etiology , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/radiotherapy , Radiation Injuries/etiology , Radiotherapy, Conformal/methods , Acute Disease , Aged , Humans , Imaging, Three-Dimensional , Male , Middle Aged , Radiotherapy Dosage , Time Factors , Treatment OutcomeABSTRACT
There was performed a comparative analysis of the indicators of immediate and long-term results of chemoradiotherapy in 342 patients with squamous cell oropharyngeal carcinoma depending on hemoglobin level before and after treatment. In patients with normal level of hemoglobin a rate of response to treatment was almost two times higher than that of patients with anemia (75,3% vs. 23,5%) and complete regression of tumors was detected by more than three times often (65,4% vs. 17,6%). The overall five-year survival of patients with anemia was significantly worse than that of patients who had normal hemoglobin level (50,7% vs. 67,7%). Patients who had normal hemoglobin level at the time of discharge demonstrated a five-year overall survival of 75,7%, while those with a hemoglobin level below normal, but more than 80 g/l,--only 57,8%. Hemoglobin concentration was a significant prognostic factor for survival of patients with squamous cell carcinoma of the oral cavity and oropharynx. Low baseline of hemoglobin was also a negative prognostic factor for tumor response to treatment, especially to chemotherapy.
